Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute–Designated Cancer Program We distributed a 21-item survey on cancer screening ...
The company recently developed a novel, recombinant protein-based chip for identifying protein binding "signatures" in vitro. 1 Candidate pharmaceutical compounds are passed over a prefabricated chip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results